Stock Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors acquired 15,360 call options on the stock. This is an increase of 44% compared to the typical daily volume of 10,636 call options.

Insider Buying and Selling

In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the transaction, the director now directly owns 7,077,560 shares of the company's stock, valued at approximately $47,561,203.20. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the company's stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the transaction, the chief operating officer now directly owns 521,138 shares of the company's stock, valued at $3,288,380.78. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,341 shares of company stock valued at $393,490. 15.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC bought a new position in shares of Recursion Pharmaceuticals in the 3rd quarter worth $25,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after acquiring an additional 4,091 shares during the last quarter. KBC Group NV lifted its position in Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after buying an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank raised its stake in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after purchasing an additional 2,459 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Down 5.8 %

Shares of NASDAQ:RXRX traded down $0.46 on Tuesday, reaching $7.49. The company had a trading volume of 17,139,865 shares, compared to its average volume of 18,317,932. The stock has a 50-day moving average price of $6.90 and a 200 day moving average price of $7.02. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $15.74. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.93 billion, a P/E ratio of -4.90 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm's quarterly revenue was up 147.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.43) earnings per share. On average, equities analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.